A comprehensive view of immune system health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca gets license to develop, sell RQ Biotechnologies' pre-clinical COVID antibody therapies in US$157M deal; deal includes therapies for patients with compromised immune systems as AstraZeneca moves to build immune-focused therapy portfolio
Published: May 19, 2022 by The Peninsula
FDA lifts clinical hold on Gilead’s injectable lenacapavir HIV treatment, pre-exposure prophylaxis as Gilead changes borosilicate glass vials to aluminosilicate glass vials; hold was from concerns about drug’s compatibility with borosilicate vials
Published: May 18, 2022 by Zack's Commentary
AbbVie awarded license option for Cugene’s CUG252 Treg-selective IL-2 mutein injectable to treat autoimmune, inflammatory diseases for US$48.5M; Cugene plans Phase 1b trial in patients with autoimmune, inflammatory diseases during option period
Published: May 17, 2022 by PR Newswire
GlobalData: Neuroimmunology drug development has exploded over last decade, with nearly 220 drugs in Phase 1, 2 and 3 stages of development across eight key diseases; top 20 neuroimmunology products worth US$20.1B in 2020, set to rise to US$26.6B by 2025
Published: May 16, 2022 by GlobalData Plc
FDA approves BLA 125521 for Eli Lilly’s Taltz injectable containing ixekizumab 80 mg/mL in one formulation to treat autoimmune disease; the drug is available by prescription only and has no therapeutic equivalents
Published: May 12, 2022 by US Food and Drug Administration News (CBNB Abstracts)

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count